Follow us on...
IconTwitterlinkedin





Search News Archives
Search for a Supplier

Company Name:


Location:

Product:

E-Newsletters
E Newsletter sign up
Calendar of events
«  »
SMTWTFS
 12345
6789101112
13141516171819
20212223242526
2728293031 
Social Media
twitter
Facebook
linkedin

Novozymes Biopharma Presents Research on Recombinant Human Albumin at 2011 PepTalk Conference

publication date: Jan 10, 2011
 | 
author/source: The Scott Partnership
Download Print Send a summary of this page to someone via email.

Novozymes BiopharmaNovozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, is presenting two scientific posters on the manufacturing and use of recombinant albumin in formulation during PepTalk 2011, 10-14 January, San Diego, US. The posters cover the company's latest research in the use of recombinant human albumin and its ability to address many of the formulation challenges faced by the industry. For more information or to request a copy of the scientific posters, please visit booth #14 at PepTalk 2011 or visit www.biopharma.novozymes.com 

The first poster entitled "Recombinant human albumin: A multifunctional excipient for stable therapeutic protein formulations" demonstrates the unmatched ability of recombinant albumin to protect therapeutic proteins against chemical and physical degradation. The second, entitled "Optimizing Saccharomyces cerevisiae for the rapid development of animal-free biopharmaceutical manufacturing processes", provides insight into the benefits of the yeast strain in the production of recombinant proteins. 

The two posters offer protein scientists new insight into formulation and manufacturing and highlight how recombinant albumin can help optimize current processes. The latest innovative solutions are described, which help to overcome some of the main challenges associated with the manufacture of protein therapeutics and biologics formulation development. 

"Novozymes is delighted to present this information on the company's latest developments in recombinant albumin", said Dermot Pearson, marketing director at Novozymes Biopharma. "As one of the industry leaders, we believe that our studies significantly contribute to the development of the field and welcome the opportunity to share our advances with industry experts who can also benefit from the leading edge data." 

For further information on Novozymes products or to request a copy of the scientific posters, please visit www.biopharma.novozymes.com

About Novozymes

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. 

With over 700 products used in 130 countries, Novozymes' bioinnovations improve industrial performance and safeguard the world's resources by offering superior and sustainable solutions for tomorrow's ever-changing marketplace. 

Novozymes' natural solutions enhance and promote everything from removing trans fats in cooking, to advancing biofuels to power the world tomorrow.

Our never-ending exploration of nature's potential is evidenced by over 6,000 patents, showing what is possible when nature and technology join forces. 

Our 5,000+ employees working in research, production and sales around the world are committed to shaping business today and our world tomorrow.



blog comments powered by Disqus



Can't find what you are looking for?

Company Name:

Location:

Product:



Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have a product enquiry, please contact the supplier directly.


Lab Bulletin is published by newleaf marketing communications ltd
Lab Bulletin 2012 Media information Pack